Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Eli Lilly announces $3 billion expansion of Wisconsin facility to meet growing demand for GLP-1 drugs
CNBC's Angelica Peebles joins 'Closing Bell' to report on Eli Lilly announcing a $3 billion expansion of its Wisconsin facility to meet growing demand for GLP-1 drugs.
Zepbound Tops Wegovy for Weight Loss
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease.Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Seeking Alpha on MSN
9h
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
Given the strong demand expected for
Eli
Lilly
's (NYSE:LLY) weight loss treatment
Zepbound
(tirzepatide) in the UK, the ...
3d
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
6d
Why Is Lilly (LLY) Down 5% Since Last Earnings Report?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Tsunami warnings lifted
Images of suspect released
Biden considers pardons
Set to return after 20 years
May cut diabetes risk
Several prisons to be closed
Ethics report release blocked
Winter storm to hit US
Nadler to step aside
Billy Long to lead IRS
Joins X Games as CEO
Raw milk recall expands
Recalls over 205,000 SUVs
Satellites to create eclipses
Prenatal test spots cancer?
Syrian rebels capture Hama
Social Security chief pick
New AI tools for employees
Medellin cartel leader freed
SpaceX sets record
Taiwan's pres visits Guam
Weekly jobless claims rise
Meet with lawmakers
Jury deliberations continue
Airbus layoffs
Rockefeller tree lights up
US trade deficit shrinks
$10B AI data center in LA
Airlines to pay for delays?
Judge rejects plea deal
Delays oil output hike
Related topics
Wegovy
Novo Nordisk
Amgen
Feedback